Abstract:1531 Background: Inherited PALB2 pathogenic variants are associated with an increased lifetime risk for breast cancer development. However, the interpretation of numerous PALB2 missense variants of uncertain significance (VUS) identified in germline genetic testing remains a challenge. Here, we assessed the impact of breast cancer patient-derived VUS on PALB2 function and identified pathogenic PALB2 missense variants that may increase cancer risk. Methods: A total of seven potentially pathogenic PALB2 VUS identified in 2,279 breast cancer patients were selected for functional analysis. All these selected VUS were assessed by SIFT, Align-GVGD, and PolyPhen2 in silico and were predicted to be deleterious by at least two in silico algorithms. The p.L35P [c.104T > C] variant was also included, for which pathogenicity has been recently confirmed. The effects of the VUS on the homologous recombination (HR) activity of PALB2 were tested by U2OS/DR-GFP reporting system. Functional characterization was further validated by protein co-immunoprecipitation and RAD51 recruitment assay. Results: PALB2 variants p.L24F [c.72G > C] and p.L35P [c.104T > C] showed the most significant disruption to the HR activity of PALB2 relative to the wild-type condition, retaining only 52.2% ( p = 0.0013) and 8.5% ( p < 0.0001) of HR activity respectively. Moderate but statistically significant HR deficiency was observed for four other variants (p.P405A [c.1213C > G], p.T1012I [c.3035C > T], p.E1018D [c.3054G > C], and p.T1099M [c.3296C > T]). We found no statistical differences for the p.K628N [c.1884G > T] and p.R663C [c.1987C > T] in the HR activity compared to wild-type PALB2. The p.L24F and p.L35P variants compromised the BRCA1-PALB2 interaction and reduced RAD51 foci formation in response to DNA damage. Conclusions: We have identified a novel patient-derived pathogenic PALB2 missense variant, p.L24F [c.72G > C], that compromises PALB2-mediated HR activity. We suggest the integration of the identified pathogenic variants into breast cancer genetic counseling and individualized treatment regimens for better clinical outcomes.

A missense variant effect map for the human tumor-suppressor protein CHK2

A missense variant effect map for the human tumour suppressor protein CHK2

Functional Analysis of Patient-Derived PALB2 Missense Variants of Uncertain Significance.

Germline variant profiling of CHEK2 sequencing variants in breast cancer patients

Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

Mutation Analysis of the Checkpoint Kinase 2 Gene in Colorectal Cancer Cell Lines

Identification of a Novel CHEK2 Variant and Assessment of Its Contribution to the Risk of Breast Cancer in French Canadian Women

CHEK2 germline variants identified in familial non-medullary thyroid cancer lead to impaired protein structure and function

Association between missense variants of uncertain significance in the CHEK2 gene and hereditary breast cancer: a cosegregation and bioinformatics analysis

Functional characterization of all missense variants and comparison to in silico models of pathogenicity

Genomic ascertainment of CHEK2-related cancer predisposition

Characterization of DNA Variants in the Human Kinome in Breast Cancer

The functional impact of variants of uncertain significance in BRCA2

Comparison of Variants of Uncertain Significance in Three Regions of the Human Glucokinase Protein Using In Vitro and In Silico Analyses

A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays

In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant.

Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain

Accurate classification of BRCA1 variants with saturation genome editing

Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation

Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data

Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2